<span item_type="fundamental" item_id="ab7fb29d75039ef40c654c27d179cd59" counter_id="ST/US/ICUCW" env="prod"></span><span item_type="announcement" item_id="516103480520606082" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 293 K.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.44.</p><p></p><h3>Segment Revenue</h3><ul><li>Net revenue for the three months ended March 31, 2025, was approximately $0.3 million, reflecting sales of the QUELIMMUNE pediatric SCD therapy.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-ex99_1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Research and development expenses for the three months ended March 31, 2025, were $2.4 million, compared to $1.7 million for the same period in 2024, primarily due to increased clinical trial costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-ex99_1.htm"></span></li><li>General and administrative expenses decreased to approximately $1.7 million from $2.3 million in the prior year, due to a decline in accounting-related costs and legal expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-ex99_1.htm"></span></li><li>Net loss for the three months ended March 31, 2025, was approximately $3.8 million, or $0.44 per share, compared to a net loss of approximately $12.7 million, or $4.73 per share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was - $2.7 million for the three months ended March 31, 2025, compared to - $3.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-ex99_1.htm"></span></li><li>The company reported cash, cash equivalents, and long-term investments of $5.3 million as of March 31, 2025, compared to $1.8 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-ex99_1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>SeaStar Medical reported a four-fold increase in QUELIMMUNE net product revenue in the first quarter of 2025 to approximately $293 thousand compared to approximately $68 thousand in the fourth quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>SeaStar Medical anticipates completing the NEUTRALIZE-AKI trial and potentially filing the Premarket Approval (PMA) application in 2026. The company is actively engaging with healthcare providers to expand access to its technology in the adult AKI market.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-ex99_1.htm"></span></li></ul>

SEASTAR MEDICAL HOLDING CORP C/WTS 28/10/2027 (TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 293 K